Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13729
Title: Amyloid imaging: Past, present and future perspectives
Austin Authors: Villemagne, Victor L 
Affiliation: Molecular Imaging and Therapy
Issue Date: 2016
metadata.dc.date: 2016-01-28
Publication information: Ageing Research Reviews 2016 Jan 28. pii: S1568-1637(16)30005-8
Abstract: Abstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by the gradual onset of dementia. The pathological hallmarks of the disease are Aβ amyloid plaques, and tau neurofibrillary tangles, along dendritic and synaptic loss and reactive gliosis. Functional and molecular neuroimaging techniques such as positron emission tomography (PET) using functional and molecular tracers, in conjuction with other Aβ and tau biomarkers in CSF, are proving valuable in the differential diagnosis of AD, as well as in establishing disease prognosis. With the advent of new therapeutic strategies, there has been an increasing application of these techniques for the determination of Aβ burden in vivo in the patient selection, evaluation of target engagement and assessment of the efficacy of therapeutic approaches aimed at reducing Aβ in the brain.
URI: http://ahro.austin.org.au/austinjspui/handle/1/13729
DOI: 10.1016/j.arr.2016.01.005
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/26827784
Type: Journal Article
Subjects: Positron-Emission Tomography
Amyloid beta-Peptides
Alzheimer Disease
Neuroimaging
Appears in Collections:Journal articles

Show full item record

Page view(s)

2
checked on Dec 8, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.